Researchers at the University of Southern California have found a way to generate a potentially renewable supply of genetically engineered immune cells capable of attacking cancer and reinforcing the body's natural defenses. The approach hinges on modifying immature immune cells rather than mature ones, allowing the engineered cells to be produced continuously within the body.
The work addresses a persistent limitation in cell-based cancer immunotherapy: engineered immune cells are typically created from mature cells collected from a patient, a process that yields a finite batch and requires repeated manufacturing for repeat treatments. By starting with immature cells, the USC team developed a system that can keep generating tumor-fighting cells after they are introduced into the body.
According to the researchers, the resulting cells are designed both to target cancer directly and to strengthen the immune system's own response. That dual action could make the therapy more durable than approaches that rely on a single infusion of mature engineered cells.
The findings are preliminary and have not yet been translated into a clinical treatment. Key questions remain about how long the engineered cells persist, how effectively they reach tumors, and whether the approach is safe in human patients. The research team's next steps will likely focus on preclinical testing and, eventually, early-stage trials.
Cell therapies have become an important frontier in oncology, particularly for blood cancers, but their complexity and cost have limited wider use. A renewable, internally produced supply of cancer-fighting cells could, in principle, simplify treatment and reduce the need for repeated manufacturing cycles. The USC work adds to a growing body of research aimed at making engineered immune cells more persistent and easier to deploy.
The discovery was reported by the university and described as a system that can continuously produce tumor-fighting cells inside the body. Further details on the cell types used, the genetic modifications involved, and the experimental results were not immediately available in the initial announcement.
14
